Beta-lactam antibiotic and beta-lactamase inhibitor combinations versus carbapenem antibiotics in the treatment of infections caused by extended-spectrum beta-lactamase and carbapenem-resistant Enterobacterales
Abstract
The growing threat of antimicrobial resistance, particularly involving extended-spectrum beta- lactamase (ESBL)-producing and carbapenem-resistant Enterobacterales (CRE), has significantly challenged existing treatment options. While carbapenems have traditionally served as the gold standard for severe infections caused by ESBL-E, their widespread use has contributed to resistance and the emergence of CRE. In response, β-lactam/β-lactamase inhibitor (BL/BLI) combinations, such as ceftazidime–avibactam and piperacillin–tazobactam, have gained interest as carbapenem-sparing alternatives. Observational studies and meta-analyses suggest that BL/BLI combinations can achieve outcomes similar to carbapenems in selected, low-risk infections, particularly when guided by susceptibility testing and MIC-based dosing; however, the MERINO randomised trial found piperacillin–tazobactam to be inferior to meropenem for ESBL-producing bloodstream infections. Newer agents have shown expanded activity against KPC, OXA-48, and even metallo-β-lactamase-producing pathogens. This review highlights the evolving role of BL/BLI therapies, the need for individualised treatment strategies, and the importance of antimicrobial stewardship in curbing resistance.
References
Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645-58. https://doi.org/10.2147/IDR.S173867
Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309-18. https://doi.org/10.1179/2047773215Y.0000000030
World Health Organization. Antimicrobial resistance [fact sheet on the Internet]. Geneva: WHO; 2023 Nov 21 [cited 2025 May 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
Strathdee SA, Davies SC, Marcelin JR. Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Lancet. 2020;396(10257):1050-3. https://doi.org/10.1016/S0140-6736(20)32063-8
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079-17. https://doi.org/10.1128/CMR.00079-17
Venkataraman R, Yadav U, Shivalingegowda RK, Shrestha Y. Vaccination strategies to combat nosocomial infections. Vacunas (Engl Ed). 2023;24(1):60-7. https://doi.org/10.1016/j.vacune.2023.02.005
Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect. 2000;6(9):460-3. https://doi.org/10.1046/j.1469-0691.2000.00107.x
Jacoby GA, Munoz-Price LS. The new β-lactamases. N Engl J Med. 2005;352(4):380-91. https://doi.org/10.1056/NEJMra041359
Harris PNA, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15(4):475-85. https://doi.org/10.1016/S1473-3099(14)70950-8
McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Correlations of antibiotic use and carbapenem resistance in Enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131-3. https://doi.org/10.1128/AAC.00607-13
Smith HZ, Kendall B. Carbapenem-resistant Enterobacteriaceae. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551704/
van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017;8(4):460-9. https://doi.org/10.1080/21505594.2016.1222343
Tehrani KHME, Martin NI. β-lactam/β-lactamase inhibitor combinations: an update. MedChemComm. 2018;9(9):1439-56. https://doi.org/10.1039/c8md00342d
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Atlanta (GA): US Department of Health and Human Services, CDC; 2019. https://doi.org/10.15620/cdc:82532
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187-212. https://doi.org/10.1093/cid/ciac268
Papp-Wallace KM. The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. Expert Opin Pharmacother. 2019;20(17):2169-84. https://doi.org/10.1080/14656566.2019.1660772
Sargianou M, Stathopoulos P, Vrysis C, Tzvetanova ID, Falagas ME. New β-lactam/β-lactamase inhibitor combination antibiotics. Pathogens. 2025;14(4):307. https://doi.org/10.3390/pathogens14040307
Muhammed M, Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Comparison between carbapenems and β-lactam/β-lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis. Open Forum Infect Dis. 2017;4(2):ofx099. https://doi.org/10.1093/ofid/ofx099
Zhang H, Liang B, Wang J, Cai Y. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review. Int J Antimicrob Agents. 2021;58(4):106410. https://doi.org/10.1016/j.ijantimicag.2021.106410
Parker JK, Gu R, Estrera GA, Kirkpatrick B, Rose DT, Mavridou DAI, et al. Carbapenem-resistant and ESBL-producing Enterobacterales emerging in Central Texas. Infect Drug Resist. 2023;16:1249-61. https://doi.org/10.2147/IDR.S403448
Wilson GM, Fitzpatrick MA, Walding K, Gonzalez B, Schweizer ML, Suda KJ, et al. Evaluating the clinical effectiveness of new beta-lactam/beta-lactamase inhibitor combination antibiotics: a systematic literature review and meta-analysis. Antimicrob Steward Healthc Epidemiol. 2021;1(1). https://doi.org/10.1017/ash.2021.217
Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169-83. https://doi.org/10.1093/cid/ciaa1478
Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E. Carbapenems. J Chemother. 2013;25(1):1-17. https://doi.org/10.1179/1973947812Y.0000000032
Bush K, Bradford PA. Interplay between β-lactamases and new β-lactamase inhibitors. Nat Rev Microbiol. 2019;17(5):295-306. https://doi.org/10.1038/s41579-019-0159-8
De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014;40(3):380-7. https://doi.org/10.1007/s00134-013-3187-2
Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, et al. Continuous versus intermittent β-lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681-91. https://doi.org/10.1164/rccm.201601-0024OC
Sfeir MM, Askin G, Christos P. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis. Int J Antimicrob Agents. 2018;52(5):554-70. https://doi.org/10.1016/j.ijantimicag.2018.07.021
Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320(10):984-94. https://doi.org/10.1001/jama.2018.12163
Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024. https://doi.org/10.1093/cid/ciae403
Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299-311. https://doi.org/10.1016/S1473-3099(19)30403-7
Zhang H, Xu J, Xiao Q, Wang Y, Wang J, Zhu M, et al. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis. Int J Infect Dis. 2023;128:194-204. https://doi.org/10.1016/j.ijid.2023.01.001
Muharam NH, Maning N, Deris Z. Comparison of clinical outcome between β-lactam/β-lactamase inhibitor (BLBLI) and carbapenem for treatment of extended-spectrum β-lactamase (ESBL) urinary tract infection. Kuwait Med J. 2023;55(4):315-22.
Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439-55. https://doi.org/10.1007/s40121-018-0214-1
Gürbüz M, Gencer G. Global trends and future directions on carbapenem-resistant Enterobacteriaceae (CRE) research: a comprehensive bibliometric analysis (2020-2024). Medicine (Baltimore). 2024;103(49):e40783. https://doi.org/10.1097/MD.0000000000040783
World Health Organization. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. Geneva: WHO; 2017. Available from: https://www.who.int/publications/i/item/9789241550178
Nigg A, Brilhante M, Dazio V, Clément M, Collaud A, Gobeli Brawand S, et al. Shedding of OXA-181 carbapenemase-producing Escherichia coli from companion animals after hospitalisation in Switzerland: an outbreak in 2018. Euro Surveill. 2019;24(39):1900071. https://doi.org/10.2807/1560-7917.ES.2019.24.39.1900071
Aurilio C, Sansone P, Barbarisi M, Pota V, Giaccari LG, Coppolino F, et al. Mechanisms of action of carbapenem resistance. Antibiotics (Basel). 2022;11(3):421. https://doi.org/10.3390/antibiotics11030421
Huang E, Yang X, Leighton E, Li X. Carbapenem resistance in the food supply chain. J Food Prot. 2023;86(7):100108. https://doi.org/10.1016/j.jfp.2023.100108
Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1):e00115-20. https://doi.org/10.1128/CMR.00115-20
Nordmann P, Bouvier M, Poirel L. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland. Eur J Clin Microbiol Infect Dis. 2023;42(9):1145-52. https://doi.org/10.1007/s10096-023-04647-0
Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54(2):167-74. https://doi.org/10.1093/cid/cir790
Nasir N, Ahmed S, Razi S, Awan S, Mahmood SF. Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy. BMC Res Notes. 2019;12(1). https://doi.org/10.1186/s13104-019-4648-7
Karaiskos I, Giamarellou H. Carbapenem-sparing strategies for ESBL producers: when and how. Antibiotics (Basel). 2020;9(2):61. https://doi.org/10.3390/antibiotics9020061
Abdul-Aziz MH, Dulhunty JM, Bellomo R, Lipman J, Roberts JA. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care. 2012;2(1):37. https://doi.org/10.1186/2110-5820-2-37
Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, et al. Effect of cefepime/enmetazobactam vs piperacillin/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial. JAMA. 2022;328(13):1304-14. https://doi.org/10.1001/jama.2022.17034
Centers for Disease Control and Prevention. About CRE (carbapenem-resistant Enterobacterales) [Internet]. Atlanta (GA): CDC; 2024 Apr 11 [cited 2025 May 13]. Available from: https://www.cdc.gov/cre/about/index.html
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498-509. https://doi.org/10.1016/S1473-3099(14)70036-2
Carlier M, Roberts JA, Stove V, Verstraete AG, Lipman J, De Waele JJ. A simulation study reveals lack of pharmacokinetic/pharmacodynamic target attainment in de-escalated antibiotic therapy in critically ill patients. Antimicrob Agents Chemother. 2015;59(8):4689-94. https://doi.org/10.1128/AAC.00409-15
Rančić A, Milosavljević MN, Rosić N, Milovanović D, Folić M, Zečević DR, et al. Population pharmacokinetics of meropenem in critically ill patients. Open Med (Wars). 2024;19(1):20241004. https://doi.org/10.1515/med-2024-1004
World Health Organization. Global research agenda for antimicrobial resistance in human health. Geneva: WHO; 2023.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Nur Amelia Syahira Binti Zainudin , Nurul Ain Nabila Binti Mohd Tajul Ariffin , Siti Nur Syuhada Binti Mohd Idris

This work is licensed under a Creative Commons Attribution 4.0 International License.



